We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis generics and biosimilars division will invest €150 million during the next 3-5 years at its Kundl, Austria and Palafolls, Spain sites while phasing out production of oral APIs at Les Franqueses site